COVID-19 is the infectious disease caused by the new coronavirus (SARS-CoV-2) identified in late 2019. COVID-19 is affecting many countries globally and has been declared a pandemic by the World Health Organization (WHO).
- VLA2001 is a Vero-cell based, highly purified inactivated vaccine candidate against the SARS-CoV-2 virus, developed using the same manufacturing platform as Valneva’s Japanese encephalitis vaccine.
- Valneva announced the initiation of the vaccine program in April 2020.
- In July 2020, Valneva reached an agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine, to be manufactured at its facilities in Livingston, Scotland 1
Additional information about COVID-19
- Valneva press release: Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program